Indo Us Bio-Tech Management
Management criteria checks 4/4
Indo Us Bio-Tech's CEO is Jagdishkumar Ajudia, appointed in Nov 2017, has a tenure of 7.67 years. directly owns 54.55% of the company’s shares, worth ₹2.04B. The average tenure of the management team and the board of directors is 7.6 years and 6.9 years respectively.
Key information
Jagdishkumar Ajudia
Chief executive officer
₹1.3m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.7yrs |
| CEO ownership | 54.6% |
| Management average tenure | 7.6yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Indo Us Bio-Tech Limited (NSE:INDOUS) Stock Rockets 25% But Many Are Still Ignoring The Company
Jul 21
These 4 Measures Indicate That Indo Us Bio-Tech (NSE:INDOUS) Is Using Debt Reasonably Well
Jul 18Some Indo Us Bio-Tech Limited (NSE:INDOUS) Shareholders Look For Exit As Shares Take 26% Pounding
Mar 14Indo Us Bio-Tech Limited's (NSE:INDOUS) 32% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jan 26Is Indo Us Bio-Tech (NSE:INDOUS) A Risky Investment?
Jan 14Optimistic Investors Push Indo Us Bio-Tech Limited (NSE:INDOUS) Shares Up 37% But Growth Is Lacking
Dec 10There's Reason For Concern Over Indo Us Bio-Tech Limited's (NSE:INDOUS) Price
Oct 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | ₹163m |
| Dec 31 2024 | n/a | n/a | ₹131m |
| Sep 30 2024 | n/a | n/a | ₹117m |
| Jun 30 2024 | n/a | n/a | ₹90m |
| Mar 31 2024 | ₹1m | n/a | ₹83m |
| Dec 31 2023 | n/a | n/a | ₹105m |
| Sep 30 2023 | n/a | n/a | ₹82m |
| Jun 30 2023 | n/a | n/a | ₹81m |
| Mar 31 2023 | ₹1m | n/a | ₹72m |
| Dec 31 2022 | n/a | n/a | ₹58m |
| Sep 30 2022 | n/a | n/a | ₹57m |
| Jun 30 2022 | n/a | n/a | ₹54m |
| Mar 31 2022 | ₹1m | ₹1m | ₹51m |
| Dec 31 2021 | n/a | n/a | ₹55m |
| Sep 30 2021 | n/a | n/a | ₹59m |
| Jun 30 2021 | n/a | n/a | ₹54m |
| Mar 31 2021 | ₹1m | ₹1m | ₹49m |
| Dec 31 2020 | n/a | n/a | ₹39m |
| Sep 30 2020 | n/a | n/a | ₹28m |
| Jun 30 2020 | n/a | n/a | ₹27m |
| Mar 31 2020 | ₹1m | ₹1m | ₹25m |
| Dec 31 2019 | n/a | n/a | ₹24m |
| Sep 30 2019 | n/a | n/a | ₹22m |
| Jun 30 2019 | n/a | n/a | ₹22m |
| Mar 31 2019 | ₹2m | ₹2m | ₹21m |
Compensation vs Market: Jagdishkumar's total compensation ($USD15.00K) is below average for companies of similar size in the Indian market ($USD41.70K).
Compensation vs Earnings: Jagdishkumar's compensation has been consistent with company performance over the past year.
CEO
Jagdishkumar Ajudia (55 yo)
Mr. Jagdishkumar Devjibhai Ajudia is a Promoter and has been Managing Director & Chairman of Indo Us Bio-Tech Ltd since November 23, 2017 and its Executive & Non Independent Director since February 04, 200...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 7.7yrs | ₹1.30m | 54.55% ₹ 2.0b | |
| Chief Finance Officer | 7.5yrs | ₹318.46k | no data | |
| Company Secretary & Compliance Officer | 5.5yrs | ₹315.30k | no data | |
| Executive & Non-Independent Director | no data | ₹600.01k | 1.99% ₹ 74.8m | |
| Whole Time Director | no data | ₹621.52k | 2.91% ₹ 109.2m | |
| Head of Marketing | no data | no data | no data | |
| Head of Human Resources | 8.3yrs | no data | no data |
Experienced Management: INDOUS's management team is seasoned and experienced (7.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 21.4yrs | ₹1.30m | 54.55% ₹ 2.0b | |
| Executive & Non-Independent Director | 7.7yrs | ₹600.01k | 1.99% ₹ 74.8m | |
| Whole Time Director | 7.5yrs | ₹621.52k | 2.91% ₹ 109.2m | |
| Non-Executive Independent Director | 6.3yrs | ₹30.00k | no data | |
| Non-Executive Independent Director | 3.9yrs | no data | no data | |
| Non-Executive Independent Director | 3.9yrs | no data | no data |
Experienced Board: INDOUS's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 10:16 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indo Us Bio-Tech Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.